Core Insights - The company announced that its subsidiary, Zhejiang Daer Biotechnology Co., Ltd., has developed the first-in-class long-acting triple agonist DR10624 for treating severe hypertriglyceridemia (SHTG), which has been recognized as a breakthrough study at the AHA Scientific Sessions 2025 [1][2] - DR10624 will be presented as the opening report at the AHA 2025 conference, highlighting the scientific value and clinical prospects of the drug [1][2] Company Developments - DR10624 is a long-acting triple-target agonist that uniquely targets FGFR1c/Klothoβ (FGF21R), GLP-1R, and GCGR, making it the fastest-developing FGF21 triple-target drug [3] - The drug has shown significant efficacy in reducing liver fat and improving lipid profiles in clinical trials, with reductions in liver fat content of 58.3% to 89.2% across different dosage groups compared to a placebo group reduction of 27.2% [4] - The company has established a comprehensive R&D system from target discovery to clinical development, demonstrating its strong independent R&D capabilities [6] Industry Impact - The recognition of DR10624 at AHA 2025 marks a historic breakthrough for China's clinical research and innovative drug development in the cardiovascular field [2] - The company is transitioning from an "innovative follower" to a "field definer," aiming to provide more "Chinese solutions" for global patients through its innovative products [7] - The increasing public health threat posed by SHTG is being addressed, with DR10624 showing promise as a novel therapy for SHTG and various cardiovascular diseases [5]

有市场人士对第一财经记者表示，次新股、盘子小，再加上近期刚刚被纳入港股通，这些因素综合在一 起，促使药捷安康股价被爆炒，但公司基本面是否有足够的支撑，值得商榷。 今日午间，药捷安康也发布了股价及成交量的异常变动自愿性公告称，董事会确认，概不知悉导致股份 出现该等股价及成交量异常变动之任何原因，或任何须予公布以避免股份出现虚假市场之资料，或须予 披露之任何内幕消息。 （文章来源：第一财经） 在经历了四个交易日连续暴涨后，今日，药捷安康（02617.HK）股价上演了一场"高台跳水"行情。 今日早盘，该公司股价最大涨幅超过60%，冲到670港元/股以上；午后开盘后，股价又一路滑落，最后 以暴跌53.73%收盘，股价仅剩下192港元/股，市值跌回千亿港元以下，为762.04亿港元。 药捷安康于2025年6月23日才在港股市场挂牌交易，彼时公司IPO首发价只有13.15港元/股，公司当前股 价较首发价涨幅仍高达13.6倍。上一交易日，即9月15日，公司收盘价曾高达415港元/股，股价较IPO首 发价涨幅约30.6倍，总市值达到1647.13亿港元。 药捷安康是一家处于注册临床阶段的创新药公司，专注于发现及开发肿瘤、炎症 ...

公司市值跌回千亿港元以下。 在经历了四个交易日连续暴涨后，今日，药捷安康（02617.HK）股价上演了一场"高台跳水"行情。 今日早盘，该公司股价最大涨幅超过60%，冲到670港元/股以上；午后开盘后，股价又一路滑落，最后 以暴跌53.73%收盘，股价仅剩下192港元/股，市值跌回千亿港元以下，为762.04亿港元。 药捷安康于2025年6月23日才在港股市场挂牌交易，彼时公司IPO首发价只有13.15港元/股，公司当前股 价较首发价涨幅仍高达13.6倍。上一交易日，即9月15日，公司收盘价曾高达415港元/股，股价较IPO首 发价涨幅约30.6倍，总市值达到1647.13亿港元。 药捷安康是一家处于注册临床阶段的创新药公司，专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子 创新疗法。截至2025年6月30日，公司主要管线包括六款临床阶段候选产品及多款临床前阶段候选产 品。替恩戈替尼是药捷安康研发进度最快的产品，同时也是公司的核心产品，这是一款选择性聚焦多激 酶抑制剂，主要靶向三个关键通路——FGFR/VEGFR、JAK和Aurora激酶，但进度最快的适应证为胆管 癌，为小癌肿，公司预计在中国的注册性2期临床于 ...

Core Viewpoint - Tianfeng Securities maintains a "Buy" rating for Junshi Biosciences (02696), projecting total revenue for 2025-2027 to be 5.873 billion, 5.970 billion, and 7.125 billion yuan, with year-on-year growth rates of 2.60%, 1.64%, and 19.36% respectively, and net profit attributable to shareholders to be 827 million, 797 million, and 1.122 billion yuan, keeping previous forecasts unchanged [1] Group 1 - HLX43 demonstrates high efficacy and low toxicity, with outstanding data for EGFR wild-type NSCLC presented at the WCLC conference [1][2] - The overall objective response rate (ORR) for evaluable patients is 37.0%, with a disease control rate (DCR) of 87.0% [2] - In a subgroup analysis of EGFR wild-type non-squamous NSCLC patients, the confirmed ORR reaches 46.7%, indicating HLX43's anti-tumor activity is not dependent on PD-L1 expression levels [2][3] Group 2 - HLX07 shows impressive efficacy, potentially providing a new approach for first-line treatment of EGFR high-expressing squamous NSCLC [4] - In a phase II dose exploration study, the high-dose group achieved a median progression-free survival (mPFS) of 17.4 months, significantly higher than the standard therapy's mPFS of around 7 months [4] - Safety profiles for both HLX43 and HLX07 are reported to be manageable, with most treatment-emergent adverse events (TEAEs) being controllable [4]

Core Viewpoint - The stock price of药捷安康 (02617.HK) has surged dramatically, reaching a market capitalization of over 240 billion HKD within three months of its IPO, despite the company not having any commercialized products and reporting a loss of 123 million HKD in the first half of the year [1][7]. Market Performance - As of September 16, the market capitalization of药捷安康 reached 249.3 billion HKD, surpassing established innovative pharmaceutical companies and approaching the market leader百济神州's valuation of 300 billion HKD [2]. - The stock price increased by nearly 600% over five trading days, with a peak price of 679.5 HKD on September 16 [1][6]. Investor Dynamics - The surge in stock price is attributed to significant inflows from southbound funds, which purchased over 300 million HKD worth of shares in two days [3]. - Key investors, including康方生物 and药石科技, have seen their investments yield over 50 times returns, with康方生物's shares valued at 517 million HKD compared to an initial investment of 10 million HKD [5][6]. Clinical Development - The stock's rise was triggered by the announcement of the clinical trial approval for its core product,替恩戈替尼, which targets multiple cancer pathways [3]. - As of June 30,替恩戈替尼 was involved in nine clinical trials globally, indicating a robust pipeline despite the company's current lack of revenue [3][7]. Financial Status - The company reported a net loss of 123 million HKD in the first half of the year, with research and development expenses of 98.43 million HKD and management expenses of 27.47 million HKD [7]. - As of June 30, the company held cash and cash equivalents of 449 million HKD, with total equity of 582 million HKD [7].

Core Viewpoint - InxMed Limited is preparing for an IPO on the Hong Kong Stock Exchange, aiming to raise funds primarily for the development and commercialization of its core product, ifebemtinib [1] Company Overview - InxMed Limited, established in 2017, is an innovative drug development company focused on therapies targeting the fundamental survival mechanisms of tumors, including FAK inhibitors, RAS inhibitors, and ADC drugs [2] - The company is currently in the late clinical stage of its core product, ifebemtinib, which is a highly selective FAK inhibitor [3] Financial Performance - In the first quarter of 2024 and 2025, InxMed reported revenues of 2.472 million and 1.603 million respectively, primarily from government grants and foreign exchange gains [3] - The company incurred net losses of 209 million, 185 million, and 3 million for the years 2023, 2024, and the first quarter of 2025, with a cumulative net loss of 804 million since its inception [3] - The company has not generated any revenue from its main business operations, relying on external financing to sustain its operations [3] Funding and Valuation - From December 2018 to January 2025, InxMed completed five rounds of financing, raising nearly 130 million USD and achieving a valuation exceeding 300 million USD [4] - Notable investors include companies owned by Liu Yonghao and Guo Guangchang, holding 1.63% and 8.97% of shares respectively [4] - As of the first quarter of 2025, the company had cash and cash equivalents of 134 million USD, but faces operational expenses exceeding 30 million USD per quarter, raising concerns about its cash flow sustainability until the IPO [4]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) experienced a significant stock price increase of over 40%, attributed to the positive results of its innovative drug, Aditinib (TY-9591), in a key Phase II clinical trial for EGFR mutation advanced non-small cell lung cancer (NSCLC) [1][2] Group 1 - The stock price rose by 37.9% to HKD 21.36, with a trading volume of HKD 1.664 billion [1] - Aditinib's Phase II clinical trial results were selected for a Mini Oral presentation at the WCLC 2025 conference, highlighting its potential in treating NSCLC patients with EGFR mutations and brain metastases [1][2] - The trial involved 257 patients with EGFR mutation NSCLC and brain metastases, with a mid-term analysis showing an intracranial objective response rate (iORR) of 92.8% for Aditinib compared to 76.1% for Osimertinib, indicating significant efficacy [2]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) experienced a significant stock price increase of over 40%, currently trading at 21.36 HKD, driven by the positive results of its innovative drug, Aiduotini (TY-9591), in a key Phase II clinical trial for EGFR mutation advanced non-small cell lung cancer (NSCLC) [1][2] Group 1: Clinical Trial Results - The key registration Phase II clinical trial (NCT05948813) for Aiduotini has been selected for a Mini Oral presentation at the WCLC 2025 conference, highlighting its importance in the medical community [1] - The trial is an open-label, multi-center, randomized controlled study focusing on NSCLC patients with EGFR mutations (L858R or 19Del) and brain metastases, comparing the efficacy and safety of Aiduotini (160mg once daily) against Osimertinib (80mg once daily) [1][2] - A total of 257 patients with EGFR mutation NSCLC and brain metastases were enrolled, with a mid-term analysis based on 224 patients showing an intracranial objective response rate (iORR) of 92.8% for the Aiduotini group compared to 76.1% for the Osimertinib group, with a statistically significant P-value of 0.0006 [2]

A股方面，百济神州、复星医药、科伦药业跌逾1%，重仓A股创新药的药ETF（562050）盘中失守20日 均线。 9月16日早盘，AH创新药板块高开后震荡走低。 港股方面，大权重多数飘绿，中国生物制药、百济神州、石药集团等多股跌逾1%，100%聚焦创新药研 发的港股通创新药ETF（520880）跌近1%，截至发稿成交超1.5亿元。 值得关注的是，港股通创新药ETF（520880）场内延续溢价交易，走低区间溢价率持续抬升，显示买盘 资金强势。截至昨日，520880已连续10日吸金，金额合计超6.1亿元。 消息面，政策利好密集袭来！9月12日，国家药监局发布《关于优化创新药临床试验审评审批有关事项 的公告》，明确提出对符合要求的创新药临床试验申请设立"30日审评审批通道"，进一步推动创新药研 发提速，助力我国医药产业高质量发展。 据国家卫健委日前介绍，我国在研新药数量占全球数量的比例超过20%，跃居全球新药研发第二位。 同日，国常会审议通过《生物医学新技术临床研究和临床转化应用管理条例（草案）》。会议指出，要 推动我国生物医学技术创新发展，加快技术研发和成果转化应用，促进生物医药产业提质升级，着力塑 造发展新优势。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for its innovative drug, Anruikefen Injection (HSK21542), which is indicated for treating moderate to severe pruritus in adult patients undergoing maintenance hemodialysis [1][2]. Group 1: Drug and Application Information - Drug Name: Anruikefen Injection - Acceptance Number: CXHS2400097 - Certificate Number: 2025S02878 - Approval Number: National Drug Standard H20250014 - Application: Drug registration (domestic production) - Registration Category: Class 1 chemical drug - Dosage Form: Injection - Specification: 1ml: 0.1mg - Indication: For moderate to severe pruritus in adult patients with chronic kidney disease undergoing maintenance hemodialysis [1]. Group 2: R&D Project Overview - HSK21542 is a highly selective peripheral kappa opioid receptor agonist developed by the company - Clinical research indicates that HSK21542 Injection significantly alleviates pruritus, with primary and secondary efficacy indicators showing significant improvement over the placebo group - The safety profile of HSK21542 Injection is reported to be good and controllable - The newly approved indication was included in the priority review and approval process in July 2024 and is now approved for market release, providing better options for patients suffering from pruritus - Anruikefen Injection was first approved in May 2025 for treating mild to moderate pain after abdominal surgery, and a Phase III clinical study for its use in postoperative pain relief in orthopedic surgery is ongoing [2].